July 28, 2021Journal of the American College of Cardiology
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia
No abstract yet
We only have this paper's title and publication details.
Read it at the sourceKey expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The previous guidelines included a section on strategies for addressing hypertriglyceridemia to reduce ASCVD risk, but this new decision pathway builds on the recommendations with more details and with additional information.”
“After maximizing LDL-C lowering therapy, triglyceride lowering therapies may be considered to further lower ASCVD risk in patients with persistent hypertriglyceridemia. Therapies that have been demonstrated to improve cardiovascular outcomes in primary and secondary prevention are preferred, keeping in mind net benefit (balance of risk and harms) of those therapies.”
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Virani et al. (2021) studied this question.